Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, and Department of Surgery, University of Toronto, Toronto, Canada.
Ann Surg Oncol. 2022 Nov;29(12):7335-7348. doi: 10.1245/s10434-022-11864-y. Epub 2022 Jun 29.
Surgery is the mainstay of treatment for retroperitoneal sarcoma (RPS), but local recurrence is common. Biologic behavior and recurrence patterns differ significantly among histologic types of RPS, with implications for management. The Transatlantic Australasian RPS Working Group (TARPSWG) published a consensus approach to primary RPS, and to complement this, one for recurrent RPS in 2016. Since then, additional studies have been published, and collaborative discussion is ongoing to address the clinical challenges of local recurrence in RPS.
An extensive literature search was performed, and the previous consensus statements for recurrent RPS were updated after review by TARPSWG members. The search included the most common RPS histologic types: liposarcoma, leiomyosarcoma, solitary fibrous tumor, undifferentiated pleomorphic sarcoma, and malignant peripheral nerve sheath tumor.
Recurrent RPS management was evaluated from diagnosis to follow-up evaluation. For appropriately selected patients, resection is safe. Nomograms currently are available to help predict outcome after resection. These and other new findings have been combined with expert recommendations to provide 36 statements, each of which is attributed a level of evidence and grade of recommendation. In this updated document, more emphasis is placed on histologic type and clarification of the intent for surgical treatment, either curative or palliative. Overall, the fundamental tenet of optimal care for patients with recurrent RPS remains individualized treatment after multidisciplinary discussion by an experienced team with expertise in RPS.
Updated consensus recommendations are provided to help guide decision-making for treatment of locally recurrent RPS and better selection of patients who would potentially benefit from surgery.
手术是治疗腹膜后肉瘤(RPS)的主要方法,但局部复发较为常见。不同组织学类型的 RPS 生物学行为和复发模式存在显著差异,这对治疗策略有重要影响。Transatlantic Australasian RPS Working Group(TARPSWG)发布了原发性 RPS 的共识方法,并于 2016 年为复发性 RPS 发布了补充共识。此后,发表了更多研究,且正在进行协作讨论以解决 RPS 局部复发的临床挑战。
进行了广泛的文献检索,并在 TARPSWG 成员审查后更新了之前的复发性 RPS 共识声明。该搜索包括最常见的 RPS 组织学类型:脂肪肉瘤、平滑肌肉瘤、孤立性纤维瘤、未分化多形性肉瘤和恶性外周神经鞘瘤。
从诊断到随访评估,对复发性 RPS 的管理进行了评估。对于适当选择的患者,切除是安全的。目前可提供列线图来帮助预测切除后的预后。这些和其他新发现与专家建议相结合,提供了 36 条陈述,每条陈述都有相应的证据水平和推荐等级。在本更新文件中,更强调了组织学类型,并澄清了手术治疗的意图,是治愈性还是姑息性。总体而言,为复发性 RPS 患者提供最佳护理的基本原则仍然是由具有 RPS 专业知识的经验丰富团队进行多学科讨论后,为患者制定个体化治疗方案。
提供了更新的共识建议,以帮助指导局部复发性 RPS 的治疗决策,并更好地选择可能从手术中获益的患者。